Quick Answer
Dermata Therapeutics, Inc. reported Net Income of -$7.56 million for fiscal year 2025.
Dermata Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$7.56M +38.5% |
-$12.29M -57.6% |
-$7.79M +18.9% |
-$9.61M -21.6% |
-$7.90M -144.2% |
-$3.24M |
| Diluted EPS | -$8.16 +89.8% |
-$80.32 -100.9% |
-$39.99 | — | — | — |
| Total Assets | $7.86M +122.5% |
$3.53M -55.7% |
$7.98M +14.9% |
$6.94M -40.3% |
$11.62M +1819.9% |
$605.5K |
| Cash and Equivalents | $7.52M +137.9% |
$3.16M | — | $6.24M -42.2% |
$10.80M +1936.0% |
$530.4K |
| Stockholders Equity | $6.22M +298.7% |
$1.56M -75.4% |
$6.36M +5.5% |
$6.02M -40.4% |
$10.11M +418.0% |
-$3.18M -1412.2% |
| R&D Expense | $2.93M -64.3% |
$8.20M +101.6% |
$4.07M -28.0% |
$5.65M +63.4% |
$3.46M +115.2% |
$1.61M |
| Operating Income | -$7.77M +37.9% |
-$12.51M -55.6% |
-$8.04M +16.9% |
-$9.67M -23.1% |
-$7.86M -147.6% |
-$3.17M |
| Shares Outstanding | 2.66M +956.8% |
251,725 -3.9% |
261,998 -66.0% |
770,115 -90.8% |
8.33M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$1.69M | +46.7% | +0.5% |
| Diluted EPS | September 30, 2025 | -$1.65 | +91.9% | +0.6% |
| Total Assets | September 30, 2025 | $5.07M | -24.2% | -23.6% |
| Cash and Equivalents | September 30, 2025 | $4.66M | — | -28.0% |
| Stockholders Equity | September 30, 2025 | $3.96M | -16.5% | -29.5% |
| R&D Expense | September 30, 2025 | $504.4K | -79.0% | -18.4% |
| Operating Income | September 30, 2025 | -$1.76M | +45.4% | +0.7% |
| Shares Outstanding | September 30, 2025 | 844,457 | -49.7% | +32.4% |
- Dermata Therapeutics, Inc. reported Net Income of -$7.56 million for fiscal year 2025.
- Dermata Therapeutics, Inc. showed an increase of +38.5% in Net Income compared to the prior fiscal year.
- Dermata Therapeutics, Inc. reported Diluted EPS of $8.16 per share (loss) for fiscal year 2025.
- Dermata Therapeutics, Inc. showed an increase of +89.8% in Diluted EPS compared to the prior fiscal year.
- Dermata Therapeutics, Inc. reported Total Assets of $7.86 million for fiscal year 2025.
- Dermata Therapeutics, Inc. showed an increase of +122.5% in Total Assets compared to the prior fiscal year.
- Dermata Therapeutics, Inc. reported Cash and Equivalents of $7.52 million for fiscal year 2025.
- Dermata Therapeutics, Inc. showed an increase of +137.9% in Cash and Equivalents compared to the prior fiscal year.
- Dermata Therapeutics, Inc. reported Stockholders Equity of $6.22 million for fiscal year 2025.
- Dermata Therapeutics, Inc. showed an increase of +298.7% in Stockholders Equity compared to the prior fiscal year.
- Dermata Therapeutics, Inc. reported R&D Expense of $2.93 million for fiscal year 2025.
- Dermata Therapeutics, Inc. showed a decrease of -64.3% in R&D Expense compared to the prior fiscal year.
- Dermata Therapeutics, Inc. reported Operating Income of -$7.77 million for fiscal year 2025.
- Dermata Therapeutics, Inc. showed an increase of +37.9% in Operating Income compared to the prior fiscal year.
- Dermata Therapeutics, Inc. reported Shares Outstanding of 2.66 million shares for fiscal year 2025.
- Dermata Therapeutics, Inc. showed an increase of +956.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: